Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
Sign Up to like & getrecommendations! Published in 2017 at "American journal of surgery"
DOI: 10.1016/j.amjsurg.2016.10.006
Abstract: Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge. One option is sorafenib, although little is known about its safety and tolerance… read more here.
Keywords: recurrent hepatocellular; resection olt; gideon registry; transplantation ... See more keywords